Legal Entity of Counterparty, Type [Axis]
Hisun [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
Horizon Credit Agreement [Member]
Legal Entity [Axis]
IPR&D Drug Technology Platforms [Member]
Contingent Consideration by Type [Axis]
Ovarian Cancer [Member]
Equity Components [Axis]
Common Stock [Member]
Additional Paid in Capital [Member]
Treasury Stock [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Measurement Frequency [Axis]
Fair Value, Measurements, Recurring [Member]
Fair Value Hierarchy and NAV [Axis]
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]
Financial Instrument [Axis]
Corporate Debt Securities [Member]
Significant Other Observable Inputs (Level 2) [Member]
Significant Unobservable Inputs (Level 3) [Member]
2018 Aspire Purchase Agreements [Member]
Capital on DemandTM Sales Agreement [Member]
Business Acquisition [Axis]
EGEN Inc [Member]
Glioblastoma Multiforme Brain Cancer [Member]
Capital on Demand Agreement [Member]
Geographical [Axis]
New Jersey [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Noncompete Agreements [Member]
Range [Axis]
Minimum [Member]
Maximum [Member]
Asset Class [Axis]
IPR&D [Member]
Goodwill [Member]
2018 Aspire Purchase Agreements [Member]
Plan Name [Axis]
Inducement Option Grants [Member]
Title of Individual [Axis]
Two New Employees [Member]
Award Type [Axis]
Restricted Stock Awards [Member]
Five New Employees [Member]
Stock Options [Member]
2019 Aspire Purchase Agreements [Member]
Investment Type [Axis]
Short-term Investments [Member]
Securities Purchase Agreement [Member]
Original Warrants [Member]
Private Exchange Agreements [Member]
Warrant [Member]
Horizon Technology Finance Corporation [Member]
Variable Rate [Axis]
London Interbank Offered Rate (LIBOR) [Member]
RNA Delivery System [Member]
Purchase Agreement [Member]
Debt Instrument [Axis]
2018 Stock Incentive Plan [Member]
2007 Stock Incentive Plan [Member]
Equity Stock Awards [Member]
Scenario [Axis]
Granted Under 2018 Plan and 2007 Plan [Member]
2018 Plan [Member]
Inducement Awards [Member]
Stock Options and Restricted Stock Awards [Member]
Income Statement Location [Axis]
Research and Development Expense [Member]
General and Administrative Expense [Member]
Non-Vested Stock-Based Compensation Arrangements [Member]
2019 Bonus Program [Member]
Restricted Stock [Member]
Fair Value Earnout Milestone Liability [Member]
Payment Option One [Member]
Amended Asset Purchase Agreement Option Payment 1 [Member]
EGWU, Inc [Member]
All Other Warrants [Member]
Adjustments for New Accounting Pronouncements [Axis]
Accounting Standards Update 2016-02 [Member]
April PPP Loan [Member]
Counterparty Name [Axis]
Silicon Valley Bank [Member]
PPP Loans [Member]
May PPP Loan [Member]
Long-term Debt, Type [Axis]
Promissory Note [Member]
Underwriting Agreement [Member]
Sale of Stock [Axis]
Underwritten Offering [Member]
Additional Paid-In Capital [Member]
Payment Option Two [Member]
Amended Asset Purchase Agreement Option Payment 2 [Member]
Lawrenceville, New Jersey [Member]
Huntsville Alabama [Member]
Cover [Abstract]
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business Flag
Entity Emerging Growth Company
Entity Shell Company
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash and cash equivalents
Investment in debt securities - available for sale, at fair value
Accrued interest receivable on investment securities
Advances and deposits on clinical programs and other current assets
Total current assets
Property and equipment (at cost, less accumulated depreciation of $3,174,681 and $3,096,681, respectively)
Other assets:
Deferred tax asset
In-process research and development, net
Goodwill
Operating lease right-of-use assets, net
Other intangible assets, net
Deposits and other assets
Total other assets
Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable - trade
Other accrued liabilities
Notes payable - current portion, net of deferred financing costs
Operating lease liability - current portion
Deferred revenue - current portion
Total current liabilities
Earn-out milestone liability
Note payable, net of deferred financing costs
Operating lease liability - non-current portion
Deferred revenue - non-current portion
Total liabilities
Commitments and contingencies
Stockholders' equity:
Preferred stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at June 30, 2020 and December 31, 2019)
Common stock - $0.01 par value (112,500,000 shares authorized; 33,229,714 and 23,256,152 shares issued at June 30, 2020 and December 31, 2019, respectively, and 33,229,380 and 23,255,818 shares outstanding at June 30, 2020 and December 31, 2019, respectively)
Additional paid-in capital
Accumulated other comprehensive gain
Accumulated deficit
Total stockholders' equity before treasury stock
Treasury stock, at cost (334 shares at June 30, 2020 and December 31, 2019)
Total stockholders' equity
Total liabilities and stockholders' equity
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Treasury stock, shares
Income Statement [Abstract]
Licensing revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other (expense) income:
(Loss) gain from change in valuation of earn-out milestone liability
Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments
Investment income
Interest expense
Other (expense) income
Total other (expense) income, net
Net loss
Net loss per common share - Basic and diluted
Weighted average shares outstanding - Basic and diluted
Statement of Comprehensive Income [Abstract]
Other comprehensive (loss) gain
Changes in:
Realized (gains) losses on investment securities recognized in investment income, net
Unrealized gains on investment securities, net
Change in unrealized (loss) gain, net, on available for sale securities
Net loss
Comprehensive loss
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation and amortization
Change in fair value of earn-out milestone liability
Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments
Recognition of deferred revenue
Stock-based compensation costs
Shares issued in exchange for services
Deferred income tax asset
Amortization of deferred finance charges and debt discount associated with notes payable
Net changes in:
Accrued interest on investment securities
Advances, deposits and other current assets
Accounts payable and accrued liabilities
Net cash (used in) operating activities:
Cash flows from investing activities:
Purchases of investment securities
Proceeds from sale and maturity of investment securities
Purchases of property and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Proceeds from sale of common stock equity, net of issuance costs
Proceeds from issuance of common stock upon conversion of stock options
Proceeds from Payroll Protection Program (PPP) loans
Repayments on Payroll Protection Program (PPP) loans
Net cash provided by financing activities
Increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosures of cash flow information:
Interest paid
Cash paid for amounts included in measurement of lease liabilities:
Operating cash flows from lease payments
Non-cash financing and investing activities
Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments
Right of use assets obtained in exchange for lease liabilities
Right of use assets
Stock issued in lieu of cash bonus payments
Realized and unrealized (gains) losses, net, on investment securities
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Sale of equity through financing facilities
Sale of equity through financing facilities, shares
Issuance of common stock upon exercise of options
Issuance of common stock upon exercise of options, shares
Issuance of common stock in lieu of cash bonus
Issuance of common stock in lieu of cash bonus, shares
Common stock warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments
Realized and unrealized gains and losses, net, on investments securities
Stock-based compensation expense
Issuance of restricted stock
Issuance of restricted stock, shares
Balance
Balance, shares
Accounting Policies [Abstract]
Business Description
Basis of Presentation
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Financial Condition and Business Plan
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements
Earnings Per Share [Abstract]
Net Loss Per Common Share
Investments, Debt and Equity Securities [Abstract]
Investment in Debt Securities Available for Sale
Fair Value Disclosures [Abstract]
Fair Value Measurements
Intangible Assets, Net (Including Goodwill) [Abstract]
Intangible Assets
Payables and Accruals [Abstract]
Other Accrued Liabilities
Debt Disclosure [Abstract]
Notes and Loans Payable
Equity [Abstract]
Stockholders' Equity
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation
Hercules Warrant [Member]
Earn-out Milestone Liability
Warrants and Rights Note Disclosure [Abstract]
Warrants
Leases [Abstract]
Leases
Technology Development And Licensing Agreements
Technology Development and Licensing Agreements
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Subsequent Events [Abstract]
Subsequent Events
Short-term Investments [Abstract]
Schedule of Cost, Fair Value and Maturities of Short Term Investments
Summary of Investment Securities Gross Unrealized Gains (Losses)
Summary of Net Realized Losses On Sales of Available for Sale Securities and Investment Income Interest and Dividends
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
Schedule of Future Amortization Amounts During the Remaining Life
Schedule of Fair Value of Assets Acquired
Schedule of Other Accrued Liabilities
Schedule of Future Principle Payments, Net of Unamortized Debt Discounts
Summary of Stock Option and Restricted Stock Awards
Schedule of Assumptions Used to Determine Fair Value of Options Granted
Schedule of Changes in Earn-out Milestone Liability
Schedule of Risk Adjustment Assessment
Summary of Warrant Activity
Schedule of Weighted Average Remaining Contractual Terms
Schedule of Lease Payments and Maturity of Our Operating Lease Liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Cumulated net losses
Cash, investment securities and interest receivable
Tax benefits of EDA
Net proceeds from sale of net operating losses
Proceeds from new capital
Debt instrument, interest rate
Number of shares of common stock issuable upon exercise of warrants and equity awards
Warrants exercise price
Number of shares of common stock issued in calculation basic loss per share
Short-term investments - Fair Value
Short-term investments - Cost
Short-term investment maturities - Within 3 months, cost
Total, cost
Short-term investment maturities - Within 3 months, fair value
Total, fair value
Investments in debt securities with unrealized Gains, Less than 12 months , Fair Value
Investment securities - available for sale, Fair Value
Investments in debt securities with unrealized Gains, Less than 12 months, Unrealized Holding Gains
Unrealized Holding Gains
Interest and dividends accrued and paid
Realized gains
Investment income, net
Investment securities, available for sale
Indefinite lived intangible assets
Asset impairment charges, total
Finite-lived intangible assets acquired
Finite-lived intangible asset, useful life
Amortization expense
Finite-lived intangible assets, net
Finite-lived intangible assets, accumulated amortization
Goodwill, acquisition
2021
2022 and thereafter
Total
Intangible assets, beginning balance
Amortization
Intangible assets, ending balance
Amounts due to contract research organizations and other contractual agreements
Accrued payroll and related benefits
Accrued professional fees
Other
Total
Statistical Measurement [Axis]
Proceeds from lines of credit, total
Interest expense, debt, total
Amortization of debt issuance costs
Proceeds from loan
Loan repayment date
Loan amount
Debt instrument face amount
Common stock shares issued
Net proceeds from issuance of common stock
Interest accrued on loan
2021
2022
2023
2024 and thereafter
Subtotal of future principal payments
Unamortized debt issuance costs, net
Total
Shelf registration statement amount
Aggregate offering price, additions
Aggregate offering price, term
Stock issued during period, shares, new issues
Proceeds from issuance of common stock
Aggregate offering price
Aggregate value available for issuance
Shares issued, price per share
Number of warrants to purchase common stock
Warrants term
Shares purchased, price per share
Underwriting discount price per share
Percentage of underwriting discount on public offering price
Equity awards, number of stock authorized
Number of equity awards available for future issuance
Number of stock options granted, during period
Stock options, strike price description
Number of shares issued
Inducement option grant, exercise price per share
Option vested period
Number of shares reserved for future issuance
Compensation cost
Unrecognized compensation cost related to non-vested stock based compensation
Stock based compensation cost expected to be recognized, weighted average period
Annual bonus awards, percentage
Gross proceeds from issuance of common stock upon exercise of stock option
Shares of common stock issued upon exercise of stock option
Number Outstanding, Outstanding, Beginning Balance
Number Outstanding, Granted
Number Outstanding, Options exercised
Number Outstanding, Vested and issued
Number Outstanding, Forfeited, cancelled or expired
Number Outstanding, Ending Balance
Number Outstanding, Exercisable
Weighted Average Exercise Price, Outstanding, Beginning Balance
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Options exercised
Weighted Average Exercise Price, Vested and issued
Weighted Average Exercise Price, Forfeited, cancelled or expired
Weighted Average Exercise Price, Outstanding, Ending Balance
Weighted Average Exercise Price, Exercisable
Weighted Average Remaining Contractual Term (years), Outstanding, Ending Balance
Weighted Average Remaining Contractual Term (years), Exercisable
Aggregate Intrinsic Value, Outstanding, Ending Balance
Aggregate Intrinsic Value, Exercisable
Number Outstanding, Non-vested stock awards outstanding, Beginning Balance
Number Outstanding, Non-vested stock awards outstanding, Granted
Number Outstanding, Non-vested stock awards outstanding, Options exercised
Number Outstanding, Non-vested stock awards outstanding, Vested and issued
Number Outstanding, Non-vested stock awards outstanding, Forfeited
Number Outstanding, Non-vested stock awards outstanding, Ending Balance
Weighted Average Grant Date Fair Value, Non-vested stock awards, Beginning Balance
Weighted Average Grant Date Fair Value, Non-vested stock awards, Granted
Weighted Average Grant Date Fair Value, Non-vested stock awards, Options exercised
Weighted Average Grant Date Fair Value, Non-vested stock awards, Vested and issued
Weighted Average Grant Date Fair Value, Non-vested stock awards, Forfeited
Weighted Average Grant Date Fair Value, Non-vested stock awards, Ending Balance
Aggregate Intrinsic Value, Outstanding, Non-vested stock awards, Ending Balance
Risk-free interest rate, minimum
Risk-free interest rate, maximum
Expected volatility, minimum
Expected volatility, maximum
Expected life (in years)
Expected dividend yield
Payments for earnout milestone liability
Payments for earnout milestone liability in cash
Earnout milestone liability
Gain on non-cash benefit
Risk adjusted assessment of each milestone
Gain (loss) from change in fair value of earn out milestone liability
Earn-out liabilities, beginning balance
Non-cash loss from the change in fair value
Earn-out liabilities, ending balance
Risk-adjustment Assessment of achieving each Milestone
Discount Rate
Estimated Time to Achieve
Number of Warrants Issued, Warrants Outstanding, Beginning Balance
Number of Warrants Issued, Warrants Issued
Number of Warrants Issued, Warrants Outstanding, Ending Balance
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance
Weighted Average Exercise Price, Warrants Issued
Weighted Average Exercise Price, Warrants Outstanding, Ending Balance
Aggregate Intrinsic Value of Outstanding Warrants
Number of Warrants Issued
Weighted Average Exercise Price
Weighted Average Contractual Terms Remaining (in years)
Accounting Standards Update [Axis]
Area of land
Lease expiration date
ROU asset
Operating lease liabilities
Other liabilities
Increased ROU asset
Operating lease expense
Operating lease costs
Remainder of 2020
2021
2022
2023
2024 and thereafter
Subtotal future lease payments
Less imputed interest
Total lease liabilities
Weighted average remaining life
Weighted average discount rate
Non-refundable research and development fee
Deferred revenue
Deferred revenue amortization period
Upfront payment
Payment of legal fees
Represents Controlled Equity Offering Sales Agreement (the “ATM Agreement”) with Cantor Fitzgerald & Co., as sales agent.
Within One Year of Achieving Milestone [Member]
Represents the additional aggregate offering price for shares of common stock that the Company may offer and sell through a sales agent.
Aggregate offering price, term.
Aggregate offering price.
Aggregate value available for issuance.
All Other Warrants [Member]
Amended Asset Purchase Agreement [Member]
Amended Asset Purchase Agreement Option Payment 1 [Member]
Amended Asset Purchase Agreement Option Payment 2 [Member]
Aspire Capital Fund, LLC [Member]
Aspire Purchase Agreement [Member]
2018 Aspire Purchase Agreements [Member]
Asset Purchase Agreement [Member]
The current amount of amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
Amount of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position.
Capital on Demand Agreement [Member]
Capital on DemandTM Sales Agreement [Member]
The amount of cash, investment securities and interest receivable.
10 Business Days of Achieving Milestone [Member]
Common Stock Sales Agreement [Member]
Controlled Equity Offering SM Sales Agreement [Member]
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) unrealized gain less than 12 months.
Amount of accumulated unrealized gain on investment in debt security measured at fair value with change in other comprehensive income (available-for-sale), unrealized gain for less than 12 months.
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with single maturity date and allocated without single maturity date, maturing in next rolling three months.
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling three months.
Duke University [Member]
EGEN Asset Purchase Agreement [Member]
Information pertaining to the business acquisition of EGEN, Inc.
EGEN Inc [Member]
EGWU, Inc [Member]
Equity Stock Awards [Member]
Exercise Agreements [Member]
Exercise Price One [Member]
Exercise Price Two [Member]
Fair Value Earnout Milestone Liability [Member]
Represents the public offering on February 14, 2017.
February 14, 2017 Public Offering [Member]
Federal Income Tax [Member]
Final Year [Member]
1st Lease Amendment [Member]
First Tranche [Member]
First Year [Member]
Five New Employees [Member]
General and Administrative Expenses [Member]
Glioblastoma Multiforme Brain Cancer [Member]
Represents a loan agreement with Hercules Technology Growth Capital, Inc. (“Hercules”).
Represents Hercules Technology Growth Capital, Inc..
Hercules Technology Growth Capital, Inc. [Member]
Represents Hercules Technology Growth Capital, Inc..
Hisun Agreement [Member]
Hisun [Member]
Horizon Credit Agreement [Member]
Horizon Technology Finance Corporation [Member]
Horizon Warrants [Member]
Huntsville Alabama [Member]
IPR&D Drug Technology Platforms [Member]
IPR&D [Member]
In Process R and D - GBM Two [Member]
Inducement Awards [Member]
Inducement Option Grants [Member]
Investor Warrants [Member]
Represents the information pertaining to the direct offering agreement on July 6, 2017.
June 2016 Warrants [Member]
Lawrenceville New Jersey [Member]
Lease Contract Type [Axis]
License Agreement [Member]
Loan Agreement [Member]
Represents a securities purchase agreement with certain investors into which the entity entered in May 2015.
New Jersey [Member]
Net proceeds from sale of net operating losses
Represents the total number of Shares of common stock issuable upon exercise of warrants and equity awards.
Number of shares of common stock issued in calculation basic loss per share.
Represents the October 2017 Underwritten Offering.
Operating Leases [Member]
Oppenheimer & Co. Inc. [Member]
Original Warrants [Member]
Other Warrant [Member]
Ovarian Cancer [Member]
Information relating to Pre-Funded Series BB Warrant.
Represents the information pertaining to the Pre-Funded Series CCC Warrants.
Private Exchange Agreements [Member]
Purchase Agreement [Member]
Recognized Non-cash Charge [Member]
Recognized Non-cash Benefit [Member]
Reduction in Warrant [Member]
Revenue Ratably Through 2022 [Member]
2nd Lease Amendment [Member]
Second Tranche [Member]
Securities Purchase Agreement [Member]
Represents the information pertaining to the Series AAA Warrants.
Information relating to Series AA warrants.
Represents the information pertaining to the Series BBB Warrants.
Represents the information pertaining to Series DDD Warrants.
Shelf Registration statement.
60 Month Lease [Member]
Tax benefits of EDA
Tax Reform Act [Member]
Three New Employees [Member]
2018 Stock Incentive Plan [Member]
2007 Stock Incentive Plan [Member]
2018 Aspire Purchase Agreements [Member]
Represents the information pertaining to the 2015 Warrants.
2019 Aspire Purchase Agreements [Member]
Represents the information pertaining to the 2013 Warrants, 2014 Warrants, and June 2016 Warrants.
U.S. Federal and State Tax [Member]
Underwriting Agreement [Member]
Warrant Exchange Agreements [Member]
Summary of stock option and restricted stock awards [Table text block]
RNA Delivery System [Member]
2023 and thereafter.
2007 Stock Incentive Plan [Member]
Stock options, strike price description.
Two New Employees [Member]
Granted Under 2018 Plan and 2007 Plan [Member]
2018 Plan [Member]
Stock Options and Restricted Stock Awards [Member]
Non-Vested Stock-Based Compensation Arrangements [Member]
2019 Bonus Program [Member]
Annual bonus awards, percentage
Payment Option One [Member]
Payment Option Two [Member]
April PPP Loan [Member]
Silicon Valley Bank [Member]
PPP Loans [Member]
May PPP Loan [Member]
Underwritten Offering [Member]
Underwriting discount price per share.
Percentage of underwriting discount on public offering price.
Weighted Average Exercise Price, Options exercised.
Finite-lived intangible asset, expected amortization, year two, and after.
Number Outstanding, Non-vested stock awards outstanding, Options exercised.
Weighted Average Grant Date Fair Value, Non-vested stock awards, Options exercised.
Gain (loss) from change in valuation of earn-out milestone liability.
Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments.
The amount recognized in earnings related to the change in fair value during the period of milestone liability.
Shares issued in exchange for services.
Amortization of deferred finance charges and debt discount associated with note payable.
Fair value of warrants issued in connection with amendment to modify the related earn-out milestone payments.
Right of use assets obtained in exchange for lease liabilities.
Right of use assets, obtained in exchange for lease liabilities.
Sale of equity through financing facilities.
Sale of equity through financing facilities, shares.
The disclosure related to earn-out milestone liabilities.
Warrants [Text Block]
The entire disclosure for a contractual arrangement, in which the Company gave another party an exclusive license.
The disclosure of transactions regarding the changes in earn-out liabilities during the period.
Schedule of risk-adjustment assessment [Table text block]
Tabular disclosure of weighted average remaining contractual terms.
Earnout milestone liability.
Gain on non-cash benefit.
The percentage of risk-adjusted assessment of each milestone.
The amount of gain (loss) from the change in the fair value of earn-out milestone liability.
Earn-out liabilities, beginning balance.
Risk-adjustment assessment of achieving each milestone.
Discount rate on milestone liabilites.
Estimated time to achieve milestone liability.
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.
Sharebased compensation arrangement by sharebased payment award non options outstanding intrinsic value.
Weighted Average Exercise Price, Warrants issued
Year four and there after.
The amortization period for deferred revenue.
Upfront payment.
Stock issued in lieu of cash bonus payments.
Issuance of common stock in lieu of cash bonus.
Issuance of common stock in lieu of cash bonus, shares.
Payments for earnout milestone liability.
Payments for earnout milestone liability in cash.
clsn_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsAmortizedCost
Assets, Current
Assets, Noncurrent
Assets
Liabilities, Current
Liabilities
Stockholders' Equity before Treasury Stock
Treasury Stock, Value
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Interest and Debt Expense
Nonoperating Income (Expense)
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Loss from change in valuation of earn-out milestone liability
Contract with Customer, Liability, Revenue Recognized
Increase (Decrease) in Accrued Investment Income Receivable
Increase (Decrease) in Prepaid Expense and Other Assets
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Available-for-sale Securities
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Payments for Loans
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Interest Paid, Excluding Capitalized Interest, Operating Activities
Shares, Outstanding
Cost
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value
Less than 12 months, unrealized gains, fair value
Unrealized gains (losses)
Amortization of Intangible Assets
Long-Term Debt, Maturity, Year One
Debt Issuance Costs, Net
Long-term Debt
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
EarnoutMilestoneLiability
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
clsn_AmountOfTimeAfterEffectiveDateOfLicenseAgreementForRegistrationRightsToTakePlace
clsn_NumberOfTrademarkProtectionApplicationPendingForThermoDox
Lessee, Operating Lease, Liability, to be Paid, Year One
Lessee, Operating Lease, Liability, to be Paid, Year Two
Lessee, Operating Lease, Liability, to be Paid, Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount